American Century Companies Inc. Lowers Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

American Century Companies Inc. decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 35.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 506,425 shares of the company's stock after selling 275,691 shares during the quarter. American Century Companies Inc. owned about 0.87% of Twist Bioscience worth $24,957,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Artisan Partners Limited Partnership lifted its stake in Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company's stock worth $137,241,000 after acquiring an additional 1,961,621 shares during the period. Dimensional Fund Advisors LP lifted its position in Twist Bioscience by 29.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company's stock valued at $46,732,000 after buying an additional 284,884 shares during the period. Baillie Gifford & Co. lifted its position in Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company's stock valued at $42,116,000 after buying an additional 132,770 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Twist Bioscience by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 448,232 shares of the company's stock valued at $16,522,000 after buying an additional 5,728 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock valued at $15,187,000 after buying an additional 300,891 shares during the period.

Analysts Set New Price Targets

Several brokerages have commented on TWST. TD Cowen raised their price objective on Twist Bioscience from $55.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, June 13th. The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, July 9th. Barclays lowered their price objective on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Finally, Robert W. Baird raised their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an "outperform" rating in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $48.22.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 5,139 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the completion of the sale, the chief executive officer now directly owns 499,593 shares in the company, valued at approximately $19,948,748.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of the business's stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total transaction of $205,200.27. Following the completion of the sale, the chief executive officer now directly owns 499,593 shares in the company, valued at approximately $19,948,748.49. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis Cho sold 709 shares of the business's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the sale, the insider now owns 78,996 shares of the company's stock, valued at $3,154,310.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,125 shares of company stock worth $664,784. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 2.1 %

Shares of NASDAQ:TWST traded up $0.97 on Thursday, hitting $47.99. 528,519 shares of the company traded hands, compared to its average volume of 1,005,147. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90. The stock has a 50 day simple moving average of $47.50 and a 200-day simple moving average of $42.91. The company has a market cap of $2.81 billion, a PE ratio of -13.99 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The business had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the business posted ($1.01) earnings per share. Twist Bioscience's quarterly revenue was up 27.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.